Asset Details
Do you wish to reserve the book?
Lecanemab in Early Alzheimer’s Disease
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Lecanemab in Early Alzheimer’s Disease
Do you wish to request the book?
Lecanemab in Early Alzheimer’s Disease
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Lecanemab in Early Alzheimer’s Disease
2023
Overview
In a phase 3 trial, participants with early Alzheimer’s disease who received the monoclonal antibody lecanemab had less decline on measures of cognition and function at 18 months than those who received placebo.
Publisher
Massachusetts Medical Society
Subject
/ Aging
/ Alzheimer Disease - diagnostic imaging
/ Alzheimer Disease - drug therapy
/ Amyloid beta-Peptides - cerebrospinal fluid
/ Antibodies, Monoclonal, Humanized - adverse effects
/ Antibodies, Monoclonal, Humanized - pharmacology
/ Antibodies, Monoclonal, Humanized - therapeutic use
/ COVID-19
/ Dementia
/ Edema
/ Humans
/ Memory
/ Nootropic Agents - adverse effects
/ Nootropic Agents - pharmacology
/ Nootropic Agents - therapeutic use
/ Placebos
